# US 2022/0072122 A1 · Method for generating recombinant poxviruses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0072122 A1
- Document ID: US20220072122A1
- Status: Published application
- Kind: A1
- Application number: 17/365,746
- Filed: 2021-07-01
- Published: 2022-03-10
- Earliest claimed: 2020-07-01
- Assignees: University of Connecticut
- Applicants: University of Connecticut
- Inventors: Paulo H. Verardi; Brittany Jasperse; Caitlin M. O'Connell; Yuxiang Wang
- Web page: https://patentgrep.com/patent/US20220072122A1

## CPC

- A61K 39/275: Poxviridae, e.g. avipoxvirus
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 15/86: Viral vectors
- A61K 2039/5256: {expressing foreign proteins}
- C12N 2710/24034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2710/24041: Use of virus, viral particle or viral elements as a vector
- C12N 2710/24051: Methods of production or purification of viral material
- C12N 2710/24143: viral genome or elements thereof as genetic vector
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Disclosed herein are methods for the rapid generation of recombinant viruses, for example, to enable vaccine development.

## Claims

### Claim 1

A method of generating recombinant vaccina viruses (rVACVs), comprising homologously recombining a replication-inducible VACV (vIND) parenteral virus and a DNA shuttle vector to generate the rVACVs.

### Claim 2 (depends on 1)

The method of claim 1, further comprising transfecting the DNA shuttle vector into parental vIND-infected cells and optionally purifying the rVACVs from the parental vIND.

### Claim 3

(canceled)

### Claim 4

(canceled)

### Claim 5

(canceled)

### Claim 6

(canceled)

### Claim 7 (depends on 2)

The method of claim 2, wherein the rVACVs further express enhanced green fluorescence protein, and the method further comprises collecting enhanced green fluorescence protein (EGFP+) plaques between a first purification step and a second purification step, and collecting the EGFP+ plaques after a purification step to obtain purified a rVACV clone and optionally amplifying the purified rVACV clone.

### Claim 8

(canceled)

### Claim 9 (depends on 2)

The method of claim 2, wherein transfecting comprises adding an rVACV inducer, wherein the rVACV inducer is a tetracycline antibiotic.

### Claim 10

(canceled)

### Claim 11

(canceled)

### Claim 12 (depends on 9)

The method of claim 9, wherein the tetracycline antibiotic is selected from chlortetracycline, oxytetracycline, tetracycline, demethylchlortetracycline, rolitetracycline, lymecycline, clomocycline, methacycline, doxycycline, minocycline, and tertiary-butylglycylamidominocycline.

### Claim 13

(canceled)

### Claim 14

(canceled)

### Claim 15

(canceled)

### Claim 16 (depends on 1)

The method of claim 1, wherein the rVACV further comprises a screening marker selected from dsRed, EGFP, gusA, or lacZ.

### Claim 17

(canceled)

### Claim 18 (depends on 1)

The method of claim 1, wherein the DNA shuttle vector comprises a promotor and a gene of interest (GOI) flanked by regions homologous to the vIND parenteral virus genome.

### Claim 19 (depends on 18)

The method of claim 18, wherein the homologous regions comprise an essential gene controlled by the inducible mechanism and its upstream gene.

### Claim 20

(canceled)

### Claim 21

(canceled)

### Claim 22

(canceled)

### Claim 23

(canceled)

### Claim 24 (depends on 1)

The method of claim 1, wherein the rVACVs are recombinant poxviruses.

### Claim 25 (depends on 24)

The method of claim 24, wherein the recombinant poxvirus is selected from the group consisting of recombinant orthopoxvirus, recombinant parapoxvirus, recombinant yatapoxvirus, recombinant molluscipoxvirus, and recombinant avipoxviruses.

### Claim 26

(canceled)

### Claim 27

A method of generating recombinant poxviruses, comprising homologously recombining a let-inducible parental VACVa transfer vector to generate the recombinant poxviruses.

### Claim 28 (depends on 27)

The method of claim 27, wherein the recombinant poxvirus is selected from the group consisting of recombinant orthopoxvirus, recombinant parapoxvirus, recombinant yatapoxvirus, recombinant molluscipoxvirus, and recombinant avipoxviruses

### Claim 29

(canceled)

### Claim 30 (depends on 27)

The method of claim 27, wherein the tet-inducible parental VACV inducibly expresses the E8R gene, the A3L gene, or the A6L gene.

### Claim 31 (depends on 27)

The method of claim 27, wherein the transfer vector comprises an A/T-rich stretch of about 20 base pairs, a 6 base pair spacer region, and a highly conserved TAAAT(A/G) (SEQ ID NO: 1) transcriptional initiator element.

### Claim 32

(canceled)

### Claim 33

(canceled)

### Claim 34

(canceled)

### Claim 35

(canceled)

### Claim 36 (depends on 27)

The method of claim 27, further comprising purifying the tet-inducible parental VACV, wherein the first purification step and a second purification step each independently comprise infecting parental VACV-infected cells with cell lysate.

### Claim 37 (depends on 35)

The method of claim 35, wherein the rVACVs further express enhanced green fluorescence protein, and the method further comprises collecting enhanced green fluorescence protein (EGFP+) plaques between the first purification step and the second purification step, and collecting the EGFP+ plaques after the second purification step to obtain a purified recombinant poxvirus clone.

### Claim 38

(canceled)

### Claim 39 (depends on 37)

The method of claim 37, further comprising amplifying the purified recombinant poxviruses clone.

### Claim 40 (depends on 27)

The method of claim 27, further comprising preparing a vaccine or medicament from the purified recombinant poxviruses clone.

### Claim 41

(canceled)

### Claim 42

(canceled)

### Claim 43

(canceled)

### Claim 44

(canceled)

### Claim 45

(canceled)

### Claim 46

(canceled)

### Claim 47 (depends on 40)

A method of inducing an immune response, comprising administering one the vaccine or medicament of claim 40 to a subject in need of such treatment.

### Claim 48 (depends on 47)

The method of inducing an immune response of claim 47, wherein the recombinant poxvirus is selected from the group consisting of recombinant orthopoxvirus, recombinant parapoxvirus, recombinant yatapoxvirus, recombinant molluscipoxvirus, and recombinant avipoxviruses.

### Claim 49

(canceled)

### Claim 50

(canceled)

### Claim 51

(canceled)

### Claim 52

(canceled)
